FDA advisory panel rejects widespread Pfizer booster shots

National News

According to J&J, the booster dose of the vaccine “generated a rapid and robust increase in spike-binding antibodies” 28 days after the primary single-dose shot in participants between the ages of 18 and 55 and in those 65 years and older. (AP Photo/Rahmat Gul, file)

WASHINGTON (AP) — An influential federal advisory panel has soundly rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans.

The vote Friday, 16-3, was a blow to the Biden administration’s effort to shore up people’s protection against the virus amid the highly contagious delta variant.

Over several hours of discussion, members of the Food and Drug Administration panel of outside experts voiced frustration that Pfizer had provided little data on the safety of extra doses.

And they complained that data provided by Israeli researchers about their booster campaign might not be suitable for predicting the U.S. experience.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Local Sports

More Local Sports

World News

More World News

Trending Stories

Washington DC Bureau

Washington DC Bureau

Newsfeed Now

More Newsfeed Now